Galecto, Inc. Common Stock (GLTO)
Galecto, Inc. (GLTO) is a biotechnology company focused on developing and commercializing treatments for fibrosis and cancer. It specializes in small molecule therapeutics targeting galectin proteins, which play a role in various pathological processes. The company's therapies aim to address unmet medical needs in diseases characterized by fibrosis and tumor progression.
Company News
Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.
Galecto, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences, including the Oppenheimer 35th Annual Healthcare Life Sciences Conference, Leerink Partners Global Healthcare Conference, and 37th Annual ROTH Conference.
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nvidia was the subject of two bullish analyst notes on Tuesday.
